公开(公告)号：US12194078B2

公开(公告)日：2025-01-14

申请号：US17869863

申请日：2022-07-21

Applicant: Cartesian Therapeutics, Inc.

Inventor： Lloyd Johnston

IPC: A61K38/44 ,  A61K9/51 ,  A61K38/43 ,  A61K45/00 ,  A61P29/00 ,  A61P37/06 ,  A61K31/165 ,  A61K31/192 ,  A61K31/436 ,  A61K31/445 ,  A61K31/573 ,  A61K45/06

Abstract: Provided herein are methods and compositions, such as kits, related to compositions comprising synthetic nanocarriers comprising an immunosuppressant and compositions comprising an uricase and a composition comprising an anti-inflammatory therapeutic. Also provided herein are methods and compositions for the treatment of subjects in need of administration or treatment with the uricase.

公开(公告)号：US20240344030A1

公开(公告)日：2024-10-17

申请号：US18292670

申请日：2022-07-28

Applicant: Cartesian Therapeutics, Inc.

Inventor： Yi Zhang ,  C. Andrew Stewart ,  Metin Kurtoglu ,  Sjaji Daniel ,  Murat V. Kalayoglu ,  Minhtran Ngo Casi

IPC: C12N5/0775 ,  C07K14/54 ,  C07K14/715 ,  C07K16/28 ,  C12N15/85

CPC classification number: C12N5/0662 ,  C07K14/5434 ,  C07K14/7158 ,  C07K16/2809 ,  C07K16/2878 ,  C12N15/85 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/92 ,  C12N2800/107

Abstract: Provided here are cells engineered for therapeutic purposes to express multiple proteins, including an anti-BCMA (B cell maturation antigen), anti-CD3 bispecific antibody. Also provided are new anti-BCMA, anti-CD3 bispecific antibodies with associated sequences. Further disclosed is a mesenchymal stem cell (MSC) comprising an exogenous mRNA encoding an anti-BCMA and anti-CD3 antibody, and an exogenous mRNA encoding a single-chain interleukin-12 (IL-12) fusion protein.

公开(公告)号：US20240294600A1

公开(公告)日：2024-09-05

申请号：US18654279

申请日：2024-05-03

Applicant: Cartesian Therapeutics, Inc.

Inventor： Yi Zhang ,  C. Andrew Stewart ,  Metin Kurtoglu ,  Murat V. Kalayoglu ,  Michael S. Singer

IPC: C07K14/705 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28 ,  C07K16/30

CPC classification number: C07K14/70517 ,  A61K39/3955 ,  A61K39/39558 ,  C07K16/2878 ,  C07K16/2896 ,  C07K16/30 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/03

Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.

公开(公告)号：US20220089678A1

公开(公告)日：2022-03-24

申请号：US17540947

申请日：2021-12-02

Applicant: Cartesian Therapeutics, Inc.

Inventor： Yi Zhang ,  C. Andrew Stewart ,  Metin Kurtoglu ,  Murat V. Kalayoglu ,  Michael S. Singer

IPC: C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395

Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.

公开(公告)号：US20200291087A1

公开(公告)日：2020-09-17

申请号：US16825996

申请日：2020-03-20

Applicant: Cartesian Therapeutics, Inc.

Inventor： Yi Zhang ,  C. Andrew Stewart ,  Metin Kurtoglu ,  Murat V. Kalayoglu ,  Michael S. Singer

IPC: C07K14/705 ,  C07K16/28

Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.

公开(公告)号：US11999773B2

公开(公告)日：2024-06-04

申请号：US17540947

申请日：2021-12-02

Applicant: Cartesian Therapeutics, Inc.

Inventor： Yi Zhang ,  C. Andrew Stewart ,  Metin Kurtoglu ,  Murat V. Kalayoglu ,  Michael S. Singer

IPC: C07K16/28 ,  A61K39/395 ,  C07K14/705 ,  C07K16/30 ,  A61K39/00 ,  C07K14/715

CPC classification number: C07K14/70517 ,  A61K39/3955 ,  A61K39/39558 ,  C07K16/2878 ,  C07K16/2896 ,  C07K16/30 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/03

Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.

公开(公告)号：US11220535B2

公开(公告)日：2022-01-11

申请号：US17156407

申请日：2021-01-22

Applicant: Cartesian Therapeutics, Inc.

Inventor： Yi Zhang ,  C. Andrew Stewart ,  Metin Kurtoglu ,  Murat V. Kalayoglu ,  Michael S. Singer

IPC: C07K16/28 ,  C07K16/30 ,  C07K14/705 ,  A61K39/395 ,  C07K14/715 ,  A61K39/00

Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.

公开(公告)号：US20210221868A1

公开(公告)日：2021-07-22

申请号：US17156407

申请日：2021-01-22

Applicant: Cartesian Therapeutics, Inc.

Inventor： Yi Zhang ,  C. Andrew Stewart ,  Metin Kurtoglu ,  Murat Kalayoglu ,  Michael S. Singer

IPC: C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  A61K39/395

Abstract: Provided herein are chimeric antigen receptors (CARs), such as those specific for BCMA, that have improved properties, including increased CAR T cell binding to BCMA and improved CAR T cell killing of BCMA-expressing cancer cells. Use of the CARs in immune cells (e.g., T cells), compositions (e.g., CARs and nucleic acid constructs encoding the same), and methods are also contemplated.

公开(公告)号：US20250057756A1

公开(公告)日：2025-02-20

申请号：US18933195

申请日：2024-10-31

Applicant: Cartesian Therapeutics, Inc.

Inventor： Lloyd Johnston ,  Takashi Kei Kishimoto ,  Werner Cautreels ,  Earl Sands

IPC: A61K9/00 ,  A61K9/16 ,  A61K9/51 ,  A61K31/436 ,  A61K38/44 ,  A61K45/06 ,  A61K47/60 ,  A61P19/06 ,  A61P37/06 ,  B82Y5/00

Abstract: Provided herein are methods and compositions and kits related to uricase compositions and/or compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions and kits for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare.

公开(公告)号：US20230174944A1

公开(公告)日：2023-06-08

申请号：US17919092

申请日：2021-04-15

Applicant: Cartesian Therapeutics, Inc.

Inventor： Yi Zhang ,  C. Andrew Stewart ,  Shaji Daniel ,  Metin Kurtoglu ,  Murat V. Kalayoglu

IPC: C12N5/0775 ,  C12N9/22 ,  C07K16/28

CPC classification number: C12N5/0662 ,  C12N9/22 ,  C12Y301/21001 ,  C07K16/2878

Abstract: Provided herein are mammalian cells comprising a first exogenous nucleic acid encoding a DNAse protein and a second exogenous nucleic acid encoding another DNAse protein, such as DNASE1 protein and DNASE1L3 protein, that have improved properties, including the ability to degrades extracellular chromatin and remove Neutrophil Extracellular Traps (NETs). Use of these cells, including the use in the treatment of a subject in need thereof, is also contemplated.